 Palivizumab is dosed once a month via intramuscular (IM) injection, to be administered throughout the duration of the RSV season.Palivizumab targets the fusion protein of RSV, inhibiting its entry into the cell and thereby preventing infection.Palivizumab was approved for medical use in 1998.